Elvina Almuradova· @Dr_ElvinaA · X·· 13 hours agoScore70
Body · original
INTerpath-001: In macroscopic stage III melanoma, added value beyond neoadjuvant IO remains unclear. Next: target patients without MPR—but can vaccines overcome IO resistance? Value in stage IIB/IIC remains distinct.
#ESMO26 @Larvol @OncoAlert @myESMO
104 views · 1 like · 2 reposts · 0 replies
Conference abstracts
LBA1matched by Presidential Symposium I
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgINTerpath-001
https://esmocongress.esmo.orgSource: Elvina Almuradova · x.com